***********************************
Brakke Consulting’s
Animal Health News & Notes for September 19, 2014
Copyright © Brakke Consulting, Inc.
Editor: Lynn Fondon DVM MBA
************************************
JUMP TO:
Brakke Consulting news
Pet Dental Market Study
Market Research
earnings news
Phibro
Ridley
other news
Agrolimen
Aratana
Bayer
Dechra
Dow AgroSciences
DS Pharma
Elanco
Freshpet
Jaguar Animal Health
Merck (Neogen)
Merck (Nobilis IB)
Nature’s Variety
Neogen
Perdue Foods
Purina Veterinary Diets
Veterinarian Recommended Nutriceuticals
Vetzlife
************************************
BRAKKE CONSULTING, INC.
NEW PET DENTAL MARKET STUDY
AVAILABLE FOR PRE-ORDER
A comprehensive new study provides a definitive overview of the pet dental market. The Brakke-Ipsos Pet Dental Market Study brings together perspectives from both veterinarians and pet owners with national quantitative surveys of both.
The research quantifies pet owner awareness of the need for dental care for dogs and cats, and well as purchasing patterns for products and services from both OTC and professional sources. The study also analyzes the role of dental care in veterinary practice.
Early order subscribers to the new Pet Dental Study have the opportunity to submit two proprietary questions in either the veterinarian or pet owner questionnaires, or one in each.
The Brakke-Ipsos Pet Dental Market Study is available for $12,000. Companies that subscribe by Oct. 6, 2014 and pre-pay receive a $1,000 discount. For more information, contact John Volk, Brakke, (773) 327-4941; john@volkonline.com.
www.BrakkeConsulting.com
************************************
COMPANY EARNINGS RELEASES
> Phibro Animal Health reported results for the fiscal year ended June 30, 2014. The Animal Health division reported revenues of $431 million, increase of 12% over the prior year. Adjusted earnings before interest, tax, depreciation and amortization (EBITDA) was $100.3 million, a 21% increase over the prior year. The combined Animal Health and Mineral Nutrition division revenues were $633 million for fiscal 2014, an 8% increase over the prior year. (Animal Pharm)
> Ridley Inc. reported its financial results for fiscal year ended June 30, 2014. Revenues were $569 million, a decline of 1% compared to the prior year. Net income was $20.7 million, an increase of 12% compared to the prior year. (company website)
************************************
COMPANY NEWS RELEASES
> Neogen Corporation announced that it has entered into a strategic agreement with Merck Animal Health to market Neogen’s Igenity Dairy Heifer Program. The Igenity Dairy Heifer Program consists of genomic tests that offer commercial dairy producers essential information on the genetic potential of replacement dairy heifers. (company press release)
> Elanco and Dow AgroSciences announced a strategic research and development (R&D) agreement that will focus on developing integrated solutions to enable livestock producers to increase meat and milk production to meet the demands of the growing global population. (MarketWatch)
> Bayer announced plans to focus entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company, to position itself as a world-leading company in the field of human, animal and plant health. It is planned to float the MaterialScience business on the stock market as a separate company within the next 12 to 18 months. (company press release)
> Dechra Veterinary Products U.S. announced the availability of Levocrine Chewable Tablets (levothyroxine sodium) to its endocrinology product line. Levocrine Chewable Tablets provide levothyroxine sodium to aid in the treatment of canine hypothyroidism. (company press release)
> Vetzlife announced the launch of its Feline Oral Care Gel for Stomatitis. The product has a salmon oil flavoring agent and will be available for use in veterinary clinics. (company press release)
> VRN Veterinarian Recommended Nutriceuticals announced the launch of the Fatty Acid Target Score (FATS) test exclusively for veterinarians. The blood test determines the ratio of the pro-inflammatory omega-6 fatty acid arachodonic acid (ARA) and the anti-inflammatory omega-3 fatty acid, eicosapentaenoic acid (EPA). (company press release)
> Aratana Therapeutics announced that it is commencing an underwritten registered public offering of 4.50 million shares of its common stock at a price to the public of $9.25 per share. Aratana has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock. (PRNewswire, RTTNews)
> Jaguar Animal Health announced that it has submitted its eighth Investigational New Animal Drug application (“INAD”) with the Center for Veterinary Medicine (“CVM”) of the FDA for the treatment of insulin-resistance and metabolic syndrome in dogs. The prescription drug candidate has been previously evaluated in Phase 2 studies in humans, and is also the subject of INADs previously filed by Jaguar for the treatment of Type II diabetes in cats and metabolic syndrome in horses. (Marketwatch)
> Purina Veterinary Diets announced it is now offering new HA Hydrolyzed Canine Chicken Flavor Formula for food-allergic patients. (company press release)
> Freshpet Inc, announced it has filed with US regulators for an initial public offering of its common stock. Founded in 2006, Freshpet makes fresh, refrigerated food for dogs and cats as an alternative to dry or canned food. Freshpet reported a 38% rise in net sales to $39.7 million for six months ended June 30. (AF.reuters.com)
> Agrolimen announced it has made an investment in Nature’s Variety via formation of a joint venture. Nature’s Variety will continue to operate as in independent company. Financial terms were not disclosed. (Pet Business)
> Perdue Foods announced that it has removed all antibiotics from its chicken hatcheries. Perdue does not use antibiotics for growth promotion in its chicken production, and has not since 2007. The company does use an animal-only antibiotic to control an intestinal parasite, and will use antibiotics to treat and control illness in sick flocks. The company says it has reached a point where 95% of its chickens never receive any human antibiotics, and the remainder receive them only for a few days when prescribed by a veterinarian. (Vet Advantage – WorldPoultry.net)
> JAPAN DS Pharma Animal Health announced it has obtained marketing approval in Japan for its Consave (zonisamide) to control focal and generalized seizures associated with idiopathic epilepsy in dogs. (company communication)
> EU The European Commission has given MSD Animal Health (Merck Animal Health) marketing authorization for the poultry vaccine Nobilis IB Primo QX which protects chickens against viral infectious bronchitis (IB), caused by QX-like IB variants. Nobilis IB Primo QX will be the first vaccine developed using Sphereon technology in the EU. This process freeze dries live vaccines to small, highly soluble particles (spheres) that allow for packaging in lightweight aluminum cups in convenient dose sizes. (Animal Pharm)
***********************************
ANIMAL HEALTH NEWS
> US – BLUETONGUE RESEARCH Veterinary scientists at the University of California-Davis have learned how the bluetongue virus survives the winter. The researchers demonstrated that the bluetongue virus overwinters in female Culicoides midges that had fed on an infected animal during the previous season. The new study appears Sept. 12 in the journal PLOS ONE. (Feedstuffs)
> US – ANTIBIOTIC RESISTANCE The Obama administration announced a comprehensive set of new federal actions to combat the rise of antibiotic-resistant bacteria and protect public health. These include (1) an Executive Order directing the federal government to work domestically and internationally to reduce the emergence and spread of antibiotic-resistant bacteria and to help ensure the continued availability of effective treatments for bacterial infections; (2) A National Strategy for Combating Antibiotic-Resistant Bacteria; (3) a new PCAST report entitled Combating Antibiotic Resistance; and (4) the launch of a $20 million prize sponsored by the National Institutes of Health, Biomedical Advanced Research and Development Authority, and the FDA to facilitate the development of a rapid diagnostic test to be used by health care providers to identify highly resistant bacterial infections at the point of patient care. Details can be read at http://www.whitehouse.gov/blog/2014/09/18/new-executive-actions-combat-antibiotic-resistance-and-protect-public-health?source=govdelivery&utm_medium=email&utm_source=govdelivery (FDA)
************************************
BRAKKE CONSULTING, INC.
MARKET RESEARCH SERVICES
Look Before You Leap
Depend on Brakke Consulting to build a market study to meet your company’s needs, whether it is:
• Assessing the feasibility of a new product or technology
• Identifying the opinions and trends of veterinarians, pet owners or producers
• Determining the current market for products
With our in-house database of veterinarians and the ability to custom-tailor surveys of a wide variety of target audiences, we provide reliable insights into this unique industry. We also produce multi-client reports in a number of high-interest animal health market areas. For more information, see our website or call our Dallas office at 972-243-4033.
www.BrakkeConsulting.com
************************************
BRAKKE CONSULTING VIEWPOINT
This week’s news continues to demonstrate the interest level of the financial community in the animal health and pet markets. There is one new IPO and a secondary offering by one of the earlier IPO firms. In addition, an equity fund made an investment in a private pet food and products distribution company.
Over the past 24 months the financial community has invested billions of dollars in public and private companies. Whether or not these investments will generate the returns expected will be determined in the next couple of years. The marketplace now needs some successes to continue the momentum and interest from the financial community.
Have a great weekend!!
Ron Brakke
**********************************
This electronic newsletter is the sole property of Brakke Consulting, Inc.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting, Inc.
For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com.
Brakke Consulting, Inc.
12005 Ford Rd., Suite 530
Dallas, TX 75234 USA
English (United States) 
Portuguese